Androgen Replacement Therapy Market - By Product (Creams, Patches, Injections, Implants, and Oral Tablets), By Ingredient (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Androgen Replacement Therapy Market held USD 1736.9 million in 2020 and is to grow with a CAGR of 3.5% from 2020-2030. Androgen replacement therapy is commonly referred to as hormone replacement therapy. The results of decrease development in gonads are counteracted. Hypogonadism in men is a clinical syndrome that results in the tests failing to produce physiological testosterone levels. The primary explanation for the hypogonadism can be a test issue. The secondary reason is a problem with the primary and secondary hypothalamus or pituitary gland, or both. Main hypogonadism is caused by genetic anomalies, testicular damage, orchitis, radiation therapy or chemotherapy.

Market Dynamics and Factors:

Hypogonadism is more common in older men, men with obesity, men with co-morbidity and men with poor state of health. In addition, according to the Urology Journal's Therapeutic Advances: 2016 testosterone was one of the most widely prescribed drugs in the U.S.U.S. proposed stringent regulations Food and Drug Administration (FDA) is expected to hamper androgen replacement therapy market growth for androgen replacement therapy in the near future with the application of testosterone products because of increased risk of adverse cardiovascular events. The United States in February 2018 FDA revised its policy that testosterone replacement drug manufacturers need to change the labelling to warn patients of potential side effects, for which the risk of heart attack and stroke is increased. The growing prevalence of hypogonadism in adult men around the world is expected to fuel growth in the demand for androgen-replacement therapy market size. According to the European Urology Association: 2016 study, the prevalence of hypogonadism among middle-aged people ranges from 2.1 per cent to 12.8 per cent which will spur androgen replacement therapy market share.

Market Segmentation:

Based on the type of disease, the androgen replacement therapy industry is segmented into implants, patches, injections, creams, and oral tablets. Based on ingredient, the market is segmented into testosterone undecanoate, testosterone, testosterone enanthate, methyl testosterone and others. On the basis of distribution channel, the androgen replacement therapy market trends vary into hospitals pharmacies, retail pharmacies, and online pharmacies. Geographical breakdown and analysis of each of the aforementioned segments includes regions comprising North America, Europe, Asia-Pacific, and RoW. 

Geographic Analysis:

In Europe, the prevalence of low testosterone and hypogonadic symptoms in men between 40 and 79 years of age ranges from 2.1% to 5.7% is anticipated to drive size for androgen replacement therapy market. In addition, major companies on the market are focused on acquiring licensing agreements to acquire commercial rights for a particular country which is expected to drive growth in the Asia Pacific androgen replacement therapy market. Acerus Pharmaceuticals Corporation, for example, announced in December 2016 that it was signing an agreement giving Hyundai Pharm Co exclusive right to sell NATESTO in South Korea. Ltd., a pharmaceutical business based in South Korea.

Competitive Scenario:

Global androgen replacement therapy market, is witnessing cut throat market competition owing to presence of large-scale players. Key companies are also expanding their manufacturing facilities to cater to androgen replacement therapy demand. Key players enhancing the global androgen replacement therapy market size include Ferring Holding SA, Acerus Pharmaceuticals Corporation, Eli Lilly and Company, Upsher-Smith Laboratories, LLC, AbbVie, Inc., Bayer AG, Allergan Plc., Kyowa Kirin International Plc., Mylan N.V., Endo Pharmaceuticals, Inc., Pfizer, Inc., Clarus Therapeutics, Novartis International AG,Perrigo Company Plc.

Androgen Replacement Therapy Market Report Scope